A5027919726- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Advanced Breast Cancer Therapies
- Blood disorders and treatments
- Synthesis and biological activity
- Chromatin Remodeling and Cancer
- Antibiotics Pharmacokinetics and Efficacy
- Drug Transport and Resistance Mechanisms
- Computational Drug Discovery Methods
- Cancer Treatment and Pharmacology
- Mycobacterium research and diagnosis
- Protein Degradation and Inhibitors
- Pharmacological Effects and Toxicity Studies
- Colorectal Cancer Treatments and Studies
- Neutropenia and Cancer Infections
- Melanoma and MAPK Pathways
Hanmi Pharmaceutical (South Korea)
2014-2024
Poziotinib, a pan-human epidermal growth factor receptor 2 (HER) tyrosine kinase inhibitor, has shown potent activity againstwild type of factorreceptor(EGFR) family kinases including EGFR, HER2, and HER4 EGFR-mutant cells in vitro. Two phase I studies were conducted to determine the maximum tolerated dose (MTD), pharmacokinetics, safety, antitumor against advanced solid tumors.Standard 3+3 escalation scheme using two different dosing schedules studied: once daily, 14-day on, 7-day off...
We examined the efficacy of poziotinib, a second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) in patients with lung adenocarcinoma activating EGFR mutations, who developed acquired resistance (AR) to EGFR-TKIs.This single-arm phase II study included EGFR-mutant AR erlotinib or gefitinib based on Jackman criteria. Patients received poziotinib 16 mg orally once daily 28-day cycle. The primary endpoint was progression-free survival (PFS). Prestudy tumor...
HM30181 is a third generation P-glycoprotein (P-gp) inhibitor currently under development. The objectives of this study were to evaluate the effects single dose on pharmacodynamics and pharmacokinetics loperamide, P-gp substrate, compare them with those quinidine.Eighteen healthy male subjects administered loperamide alone (period 1) or plus quinidine in period 2 3, respectively. In randomly received one three doses: 15, 60 180 mg. Changes pupil size, alertness, oxygen saturation oral...
2570 Background: HM95573 is a novel and selective RAF kinase inhibitor which showed potent anti-tumor activities in BRAF, KRAS NRAS mutant model vitro vivo. This phase 1 trial evaluated the safety, tolerability, pharmacokinetics (PK), activity of patients with solid tumors. Interim results from study are presented here. Methods: Patients who had tumor or mutation were enrolled. was administered everyday 21-day cycle treatment has been repeated until disease progression dose-limiting toxicity...
Abstract Enhancer of zeste homolog 2 (EZH2), an enzymatic subunit polycomb repressive complex (PRC2), is known to catalyze tri-methylation histone H3 at lysine 27 (H3K27me3), leading repression the transcription its target genes involved in cell cycle regulation, proliferation, differentiation, and tumor suppression. It has been proposed that epigenetic regulators could serve as novel drug targets, EZH2 one targets with considerable therapeutic potential. Meanwhile, synthetic lethality a...
Abstract Background: Eflapegrastim is a long-acting G-CSF that comprised of analog and recombinant IgG4 Fc fragment conjugated at their N-termini via short polyethylene glycol linker. Currently, products are administered 24 hours after chemotherapy. We compared the duration neutropenia (DN) treatment with eflapegrastim pegfilgrastim given on same-day, three different timepoints, in chemotherapy-induced neutropenic rats. Method: Neutropenia was induced rats intraperitoneal administration...